All type of patients: 11 trials - OPTIMAL - EUTRAC - TITAN - TRIBUTE (Herbst) - Gatzemeier - Mok - SATURN (Cappuzzo) - Boutsikou - Lee - Stinchcombe - FASTACT-2 (Wu)
| erlotinib vs Platinum-based CT | No demonstrated result suggested progression or death (progression free survival PFS) by 73% (not demonstrated) | |
| erlotinib + Platinum-based CT vs Platinum-based CT | No demonstrated result suggested objective response (ORR) by 30% (not demonstrated) suggested death (overall survival) by 11% (not demonstrated) suggested progression or death (progression free survival PFS) by 22% (not demonstrated) |
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
